Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Protein tyrosine kinase /JAK / STAT >  JAK inhibitors >  AT9283

AT9283

Basic information Safety Supplier Related

AT9283 Basic information

Product Name:
AT9283
Synonyms:
  • 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea AT9283
  • AT9283, >=98%
  • N-cyclopropyl-N'-[3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]Urea
  • Urea, N-cyclopropyl-N'-[3-[6-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]-
  • 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea
  • CS-48
  • AT-9283; AT 9283
  • J-504568
CAS:
896466-04-9
MF:
C19H23N7O2
MW:
381.43
Product Categories:
  • Inhibitor
  • Inhibitors
Mol File:
896466-04-9.mol
More
Less

AT9283 Chemical Properties

Density 
1.45
storage temp. 
under inert gas (nitrogen or Argon) at 2–8 °C
solubility 
insoluble in H2O; ≥19.05 mg/mL in DMSO; ≥47.6 mg/mL in EtOH with ultrasonic
form 
solid
pka
10.58±0.10(Predicted)
color 
White to off-white
More
Less

AT9283 Usage And Synthesis

Uses

AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively). It also potently (IC50 = <1 μM) inhibits many other kinases, including serine/threonine kinases as well as receptor and non-receptor tyrosine kinases. As Aurora kinases have roles in mitosis, inhibitors of these kinases, including AT-9283, have potential in cancer therapy. Consistent with this, AT-9283 is effective in preventing proliferation of cancer cells both in vitro and in vivo and this effect may be enhanced by combination therapy with other chemotherapeutics.[Cayman Chemical]

Definition

ChEBI: 1-cyclopropyl-3-[3-[5-(4-morpholinylmethyl)-2-benzimidazolylidene]-1,2-dihydropyrazol-4-yl]urea is a member of benzimidazoles.

Biological Activity

at9283, a synthetic small heterocyclic molecule discovered using a fragment-based approach, is a novel inhibitor of aurora kinase, a family of serine/threonine kinases regulating both mitosis and meiosis, that potently inhibits aurora kinases a and b, with 50% inhibition concentration ic50 value of 3 nm, as well as janus kinases (jaks), abelson kinase (bcrabl t315i) and flt-3. at9283 has been found to be therapeutic in leukemic cells, myeloproliferative disorders and multiple solid tumor cell lines. study results have shown that at9283 exhibits anti-proliferative activity and induces polyploidy and apoptosis in aggressive b-cell nhl cell lines associated with inhibition of aurora kinase b.qi w, liu x, cooke ls, persky do, miller tp, squires m, mahadevan d. at9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive b-cell lymphomas. int j cancer. 2012 jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. epub 2011 nov 19.arkenau ht, plummer r, molife lr, olmos d, yap ta, squires m, lewis s, lock v, yule m, lyons j, calvert h, judson i. a phase i dose escalation study of at9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. ann oncol. 2012 may;23(5):1307-13. doi: 10.1093/annonc/mdr451. epub 2011 oct 19.

target

Aurora A

AT9283Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Email
sale@labgogo.com
More
Less

AT9283(896466-04-9)Related Product Information